EASL 2013: NS5A Inhibitor GS-5816 Looks Good in Phase 1 Study, Now In Phase 2
- Details
- Category: HCV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
The next-generation HCV NS5A inhibitor GS-5816 demonstrated potent antiviral activity against a range of viral genotypes in a preclinical study presented at the recent EASL International Liver Congress in Amsterdam (EASL 2013), paving the way for a Phase 2 trial of GS-5816 plus sofosbuvir in an interferon-free dual regimen.
EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
- Written by Liz Highleyman
Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.
EASL 2013: HIV/HCV Coinfected at Risk for Decompensation, May Need Prompt Treatment
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIV positive people with hepatitis C coinfection may experience liver decompensation with advanced fibrosis, even before they progress to cirrhosis, and may therefore benefit from earlier antiviral treatment, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: HIV/HCV Coinfected Patients More Likely to Develop Cirrhosis, but Treatment Lowers Risk
- Details
- Category: HCV Disease Progression
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
Sustained response to hepatitis C treatment leads to slow regression of liver fibrosis in people with HIV/HCV coinfection, but they remain at elevated risk for liver cirrhosis compared to those without HCV, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
Probiotics that change the population of organisms in the gut can help improve neurocognitive function and prevent hepatic encephalopathy in people with liver cirrhosis, according to a presentation last month at the EASL International Liver Congress (EASL 2013) in Amsterdam.
More Articles...
- EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
- EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
Web Design and Development by